Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?
about
Minimal Residual Disease Assessment in the Context of Multiple Myeloma TreatmentNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsNew criteria for response assessment: role of minimal residual disease in multiple myelomaOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceInhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737Consolidation in multiple myeloma - current status and perspectivesDifferentiation stage of myeloma plasma cells: biological and clinical significance.The future of autologous stem cell transplantation in myeloma.How we manage autologous stem cell transplantation for patients with multiple myelomaPost-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple MyelomaMultiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapyCombination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-rEfficient transient transfection of human multiple myeloma cells by electroporation--an appraisal.Effects of Radiotherapy in the treatment of multiple myeloma: a retrospective analysis of a Single Institution.Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell linesRenal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.RARα2 expression confers myeloma stem cell featuresImportance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.Optimal management of elderly patients with myeloma.Update on second primary malignancies in multiple myeloma: a focused review.AKT as a therapeutic target in multiple myeloma.The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis.The role of tandem stem cell transplantation for multiple myeloma patients.End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.Which therapies will move to the front line for multiple myeloma?Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsIn vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.Multiple Myeloma Minimal Residual Disease.VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomibFlow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation methodCytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cellsNext Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response.PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal.Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations
P2860
Q26768653-DF8A8201-22C1-41D8-B086-3B2EC676AF80Q26822754-1520DB30-C635-4B53-B3CE-7CB013FEF242Q27027512-358368E4-852B-4DA8-94F9-137BAC6A1A0AQ28077567-FE085467-9343-48B5-B8AD-BA0874EF0E86Q28542684-5EF79832-4698-4F6C-A6D5-3879F8E97D08Q30369423-DCABFC08-4AA2-4E9A-BA81-E0D17D87A8E9Q33712516-937388FB-C6D7-439A-81AE-CC0D1111D227Q33917164-0E714D81-A5F9-49C9-882A-5C0C5AB9BA4FQ34019581-DC48D6FB-07F1-4ECB-9E70-D5AFFAC12C8CQ34694749-80DAE6E5-F40A-4BF2-9B2B-043E7CE41E80Q35061518-3189DD73-FEFC-4797-B546-F60B6E33A709Q35180069-A9578FEC-4EE2-439E-8DAE-5564FA80CED4Q35182314-B0E13CE2-636E-43BE-B6C4-2DF9C7DB6B35Q35336626-A2633628-C8E3-4414-A7D5-06137E0A2F11Q35594600-B311580B-8B23-4702-8ECE-CCAA72638EE7Q35603608-544F18BD-4493-4DCD-A53F-E7A5699CECD2Q37037265-ABB91A6D-C61E-425C-8DE7-4E75C54AB406Q37113087-DA69F04F-5BFE-4D9B-A690-81B122E72E3AQ37411236-59DC6504-2919-497D-AF8C-2BFFC0909156Q38168925-79FBE163-23DE-45B0-8434-BAA1E3C7E5C0Q38178031-47C2B226-C67F-48F3-B698-104ADE73AB69Q38218256-990DE8C0-E9FA-4F8D-AC03-C27E299F9C17Q38674188-E38FF678-6204-45E3-8BFC-C3F19B0FB4B5Q38677358-ED6D478B-02D9-48BD-B172-AED2562DE0FFQ38732370-8169747A-8A51-48E4-81DB-8EED936576C9Q38733592-458A82AB-F275-488F-94E8-95A6791486E9Q38789282-9CEB4D99-09B9-4FE4-8D7C-819541E1A84CQ38910971-8B85D2AB-8E92-4D00-B431-641A56C7A5D1Q38970590-B9A5729D-938D-4DA6-9B6C-CD976848C560Q39103567-8A951413-E932-48B5-8D32-7A963644DEBAQ40593240-B00B7AA5-D3C2-4EBE-B0FB-1D83413A4F69Q41557109-A9C89E70-02F5-4094-A61C-4CFCFE38A640Q41923643-A2B891E9-12DB-4C0A-BBD9-F2AA6FAD3D29Q42050819-BB25402A-7604-4019-A3A7-AA457E24EDFFQ42459032-0DD26C1B-DA68-493C-ADE2-670630B719D8Q46440869-29B926D4-FD67-4D96-9608-26D8BBF9EADAQ48338656-60F5C944-C44A-4BED-ABBC-2B21E9A150AFQ53055574-915E857C-391A-434C-B6EE-E8AC1FD708FAQ54458683-AF6C3ABB-C5BF-498A-A497-50D4D761A12FQ58010072-4F82C589-364F-48BE-AC66-30D3C79B6D52
P2860
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 June 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Improvement in long-term outco ...... are patients now being cured?
@en
Improvement in long-term outco ...... are patients now being cured?
@nl
type
label
Improvement in long-term outco ...... are patients now being cured?
@en
Improvement in long-term outco ...... are patients now being cured?
@nl
prefLabel
Improvement in long-term outco ...... are patients now being cured?
@en
Improvement in long-term outco ...... are patients now being cured?
@nl
P2093
P2860
P356
P1433
P1476
Improvement in long-term outco ...... are patients now being cured?
@en
P2093
A Mitchell
B Barlogie
S Z Usmani
P2860
P2888
P304
P356
10.1038/LEU.2012.160
P577
2012-06-18T00:00:00Z